Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DMRWSGO)

Drug Name
Bay K 8644 Drug Info
Synonyms
71145-03-4; methyl 2,6-dimethyl-5-nitro-4-[2-(trifluoromethyl)phenyl]-1,4-dihydropyridine-3-carboxylate; MLS000028858; 3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, methyl ester; C16H15F3N2O4; R(+)-BAY K 8644; SMR000058424; Methyl 2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-1,4-dihydropyridine-3-carboxylate
Cross-matching ID
PubChem CID
2303
ChEBI ID
CHEMBL34555
CAS Number
CAS 71145-03-4
TTD Drug ID
D01RAD

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
Propanoate metabolism 2.15 0.00e+0 30/34 (88.24%) DLD;LDHB;HADHA;...
Oxidative phosphorylation 2.07 0.00e+0 93/133 (69.92%) ATP6V0E2;COX7A1;ATP5MC3;...
Huntington disease 1.94 1.63e-2 233/306 (76.14%) COX7A1;GPX7;ATP5MC3;...
Proteasome 1.88 2.45e-2 44/46 (95.65%) PSMB8;IFNG;PSMB9;...
Systemic lupus erythematosus 1.84 2.94e-2 45/135 (33.33%) ELANE;HLA-DRB1;FCGR2A;...
Pyrimidine metabolism 1.81 2.65e-2 40/56 (71.43%) CANT1;RRM2;NT5E;...
Prion disease 1.79 2.98e-2 209/273 (76.56%) COX7A1;PIK3R1;ATP5MC3;...
Pyruvate metabolism 1.77 3.22e-2 41/47 (87.23%) DLD;MDH2;LDHB;...
Parkinson disease 1.73 3.81e-2 176/249 (70.68%) GNAI1;COX7A1;ATP5MC3;...
Antigen processing and presentation 1.66 4.98e-2 60/78 (76.92%) HLA-DRB1;CD4;CD74;...
Protein digestion and absorption -1.91 3.09e-2 78/103 (75.73%) SLC38A2;COL5A1;MEP1B;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Bone
Osteosarcoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
U-2 OS CVCL_0042 Homo sapiens 15uM 6H
Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 0.01uM - 10uM 24H
MDA-MB-231 CVCL_0062 Homo sapiens 0.01uM - 0.74uM 24H
Breast epithelium
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF-10A CVCL_0598 Homo sapiens 0.01uM - 10uM 24H
Cervix
Cervical adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HeLa CVCL_0030 Homo sapiens 0.01uM - 10uM 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HT-29 CVCL_0320 Homo sapiens 0.01uM - 10uM 24H
Fibroblast
Nasopharyngeal carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
FIBRNPC CVCL_UK07 Homo sapiens 10uM 6H, 24H
Kidney
Normal (Immortalized)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HA1E CVCL_0284 Homo sapiens 0.01uM - 10uM 24H
Normal (Transformed)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HEK293 CVCL_0045 Homo sapiens 0.04uM - 10uM 24H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A549 CVCL_0023 Homo sapiens 0.01uM - 10uM 24H
Pancreas
Pancreatic carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
YAPC CVCL_1791 Homo sapiens 0.01uM - 10uM 24H
Peripheral blood
Acute monocytic leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
THP-1 CVCL_0006 Homo sapiens 0.04uM - 3.33uM 24H
T-cell acute lymphoblastic leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Jurkat CVCL_0367 Homo sapiens 0.01uM - 10uM 24H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
PC-3 CVCL_0035 Homo sapiens 0.01uM - 10uM 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-375 CVCL_0132 Homo sapiens 0.01uM - 10uM 24H
Umbilical vein
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HUVEC-C CVCL_2959 Homo sapiens 0.04uM - 10uM 24H